LTβR alone reduced tumour weight, no change in percentage and number of CD8+ T cells. Increase in proportion of stem-like CD8+ T cells and the ratio of stem-like to terminally exhausted CD8+T cells (SLAMF6+/TIM3+)Combined therapy resulted in significant increases in CD8+ TILs which were accompanied by improved responses to therapy and tumour regression. This evidence concerns the gene LTBR and neoplasm.